Urokinase-Type Plasminogen Activator

"Urokinase-Type Plasminogen Activator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES.

Descriptor ID	D014568
MeSH Number(s)	D08.811.277.656.300.760.910 D08.811.277.656.959.350.910 D12.776.124.125.662.884
Concept/Terms	Urokinase-Type Plasminogen Activator Urokinase-Type Plasminogen Activator Urokinase Type Plasminogen Activator Plasminogen Activator, Urokinase-Type U-Plasminogen Activator U Plasminogen Activator U-PA Urinary Plasminogen Activator Urokinase Renokinase Renokinase Abbokinase Abbokinase Kidney Plasminogen Activator Kidney Plasminogen Activator Single-Chain Urokinase-Type Plasminogen Activator Single-Chain Urokinase-Type Plasminogen Activator Single Chain Urokinase Type Plasminogen Activator

Below are MeSH descriptors whose meaning is more general than "Urokinase-Type Plasminogen Activator".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Hydrolases [D08.811.277]
Peptide Hydrolases [D08.811.277.656]
Endopeptidases [D08.811.277.656.300]
Serine Endopeptidases [D08.811.277.656.300.760]
Urokinase-Type Plasminogen Activator [D08.811.277.656.300.760.910]
Serine Proteases [D08.811.277.656.959]
Serine Endopeptidases [D08.811.277.656.959.350]
Urokinase-Type Plasminogen Activator [D08.811.277.656.959.350.910]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Blood Coagulation Factors [D12.776.124.125]
Plasminogen Activators [D12.776.124.125.662]
Urokinase-Type Plasminogen Activator [D12.776.124.125.662.884]

Below are MeSH descriptors whose meaning is related to "Urokinase-Type Plasminogen Activator".

Below are MeSH descriptors whose meaning is more specific than "Urokinase-Type Plasminogen Activator".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Urokinase-Type Plasminogen Activator" by people in this website by year, and whether "Urokinase-Type Plasminogen Activator" was a major or minor topic of these publications.

Bar chart showing 11 publications over 8 distinct years, with a maximum of 4 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	1	0	1
2005	1	0	1
2007	1	0	1
2008	3	1	4
2012	1	0	1
2013	0	1	1
2015	0	1	1
2016	0	1	1

Below are the most recent publications written about "Urokinase-Type Plasminogen Activator" by people in Profiles.

Gurka MK, Pender D, Chuong P, Fouts BL, Sobelov A, McNally MW, Mezera M, Woo SY, McNally LR. Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography. J Control Release. 2016 06 10; 231:60-7.

View in: PubMed
Lizalek J, McKenna T, Huegel K, Marsh S, Carolan A, Kobliska A, Heying E, Gardner N, Miller G, Kotecki A, Henningsen M, Lundt A, Farley J, Ellerbroek SM. Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells. Anticancer Res. 2015 Oct; 35(10):5263-70.

View in: PubMed
Ingram KG, Curtis CD, Silasi-Mansat R, Lupu F, Griffin CT. The NuRD chromatin-remodeling enzyme CHD4 promotes embryonic vascular integrity by transcriptionally regulating extracellular matrix proteolysis. PLoS Genet. 2013; 9(12):e1004031.

View in: PubMed
Gold MA, Brady WE, Lankes HA, Rose PG, Kelley JL, De Geest K, Crispens MA, Resnick KE, Howell SB. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Jun; 125(3):635-9.

View in: PubMed
Oszajca K, Bieniasz M, Brown G, Swiatkowska M, Bartkowiak J, Szemraj J. Effect of oxidative stress on the expression of t-PA, u-PA, u-PAR, and PAI-1 in endothelial cells. Biochem Cell Biol. 2008 Dec; 86(6):477-86.

View in: PubMed
Ghamande SA, Silverman MH, Huh W, Behbakht K, Ball G, Cuasay L, Würtz SO, Brunner N, Gold MA. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008 Oct; 111(1):89-94.

View in: PubMed
Olvey EL, Skrepnek GH, Nolan PE. Cost-effectiveness of urokinase and alteplase for treatment of acute peripheral artery disease: comparison in a decision analysis model. Am J Health Syst Pharm. 2008 Aug 01; 65(15):1435-42.

View in: PubMed
Sato Y, Yamada H, Iwasaki K, Tateno C, Yokoi T, Yoshizato K, Horii I. Human hepatocytes can repopulate mouse liver: histopathology of the liver in human hepatocyte-transplanted chimeric mice and toxicologic responses to acetaminophen. Toxicol Pathol. 2008 Jun; 36(4):581-91.

View in: PubMed
Yamamoto T, Tomizawa K, Fujikawa M, Sato Y, Yamada H, Horii I. Evaluation of human hepatocyte chimeric mice as a model for toxicological investigation using panomic approaches--effect of acetaminophen on the expression profiles of proteins and endogenous metabolites in liver, plasma and urine. J Toxicol Sci. 2007 Aug; 32(3):205-15.

View in: PubMed
Berkenblit A, Matulonis UA, Kroener JF, Dezube BJ, Lam GN, Cuasay LC, Brünner N, Jones TR, Silverman MH, Gold MA. A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol. 2005 Oct; 99(1):50-7.

View in: PubMed

People

Explore

Similar Concepts

Top Journals